In the center of Gamaleya began research on a new drug for coronavirus

“Clinical trials are starting now,” the scientist said in an interview with TASS.

According to Gunzburg, the research will last approximately three to four months.

“The fact that this drug is effective is already known from Western analogues,” he concluded.

Earlier, Gunzburg reported that clinical trials of a drug for the treatment of coronavirus infection based on monoclonal antibodies would begin after the New Year holidays.

Therapist, immunologist, allergist Irina Yartseva said that the new version of the recommendations of the Ministry of Health contains indications for the use of monoclonal antibodies as antiviral drugs in the treatment of coronavirus infection COVID-19.

Director of the Scientific Information Center for the Prevention and Treatment of Viral Infections Georgy Vikulov commented on the situation with the pandemic against the backdrop of the spread of the Omicron strain.